Hangzhou Xinzeyuan's first industrial "standard land" project in Lin'an District to pass the on-site acceptance of production review
Release time:
Mar 03,2023
In the morning of March 1, led by Wang Tuo, Deputy Director of the District Economic and Information Technology Bureau, the expert acceptance team arrived at our company at the first stop, in collaboration with the heads of the Industrial Investment Section of the District Economic and Information Technology Bureau, the fixed assets investment Management Section and Energy Management Section of the District Development and Reform Bureau, the Risk Management Bureau of the District Tax Bureau, the Administrative Approval Section of the Ecological Environment Lin'an Branch, the High tech and New Technology Section of the District Science and Technology Bureau, the Industrial Energy Section and Investment Section of the District Statistics and Planning Bureau, and carried out on-site acceptance for the Xinzeyuan "annual output of 128.55 million precision components production line construction" project.
Acceptance and review
The leaders of the acceptance team reviewed our company's "Standard Land" project "Annual Production of 128.55 Million Precision Components Production Line Construction" based on five indicators: investment intensity of fixed assets, average tax revenue per mu, unit energy consumption added value, unit emission added value, and R&D cost proportion. After expert review and acceptance, our company's industrial "Standard Land" project exceeded the production target and successfully passed the review, becoming the first unit in the entire district to pass the review!
Hangzhou Xinzeyuan Medical Technology Co., Ltd. was founded in 2010 and is a national high-tech enterprise specializing in the research and development, production, and sales of critical precision medical components. In recent years, the company has been deeply cultivating in the field of medical device endoscopy, aiming to become a CDMO and CRO service provider in the medical device industry. Since its establishment, the company has passed five major system certifications and has also been awarded honorary titles such as provincial-level specialized and innovative small and medium-sized enterprises, provincial-level technology-based small and medium-sized enterprises, and provincial-level high-tech enterprise research and development centers. At the same time, a research and development center was established in Shenzhen, actively building a high-tech talent team that integrates new product development and lean production.
The company has a leading product advantage in the same industry, with its main products including disposable medical biopsy forceps, disposable medical consumables, and endoscopic snake bone products. Its market share has been increasing year by year. In the future, the company will continue to make efforts and increase investment in the digestive and endoscopic series of medical equipment products.
In order to strive to build Xinzeyuan into a global medical device supply chain platform, in 2023, in response to the development of national policies and industry trends, the company has formulated strategic goals with disposable consumables, soft endoscope bodies, and animal endoscope machines as the core business segments under medical endoscopy.
Next Page
More news
